Blog - whats new?
In 2015, the U.S. Food and Drug Administration approved the first drug with cannabidiol (CBD) for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. CBD is a natural component of the Cannabis Sativa, which does not cause intoxication that comes from tetrahydrocannabinol (THC).
The formulas that we develop are created by researching, looking through scientific reviews and their comparisons. Based on scientific data, on the proven efficacy of already existing formulas, ingredients, and various combinations of ingredients, we use our own manufacturing technologies to develop new molecular compounds. One of our main priorities when developing new combinations is product safety.